A5091492845- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Childhood Cancer Survivors' Quality of Life
- Retinoids in leukemia and cellular processes
- Eosinophilic Disorders and Syndromes
- Epigenetics and DNA Methylation
- Pneumocystis jirovecii pneumonia detection and treatment
- Hematological disorders and diagnostics
- HIV/AIDS drug development and treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Immunodeficiency and Autoimmune Disorders
- Lung Cancer Treatments and Mutations
The University of Texas MD Anderson Cancer Center
2016-2025
Central State Hospital
2023
Moffitt Cancer Center
2023
Harvard University
2023
Mayo Clinic
2023
Imperial College Healthcare NHS Trust
2023
St Mary's Hospital
2023
Imperial College London
2023
Institut Gustave Roussy
2023
Inserm
2023
Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% relapse. Relapsed or refractory AML (R/R-AML) remains particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin combined B-cell lymphoma-2 inhibitor venetoclax in ND-AML R/R-AML.The IB portion...
BACKGROUND The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that HCVAD dasatinib in patients Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) a randomized trial. METHODS authors analyzed 110 newly diagnosed Ph+ ALL who were enrolled 2 consecutive, prospective, phase trials frontline either (63 patients) or (47 patients). Propensity score analysis 1:1 matching the...
Several important treatment and supportive care strategies have been implemented over the past 4 decades in management of acute myeloid leukemia (AML).The authors identified 29,107 patients who were diagnosed with de novo AML between 1980 2017 National Cancer Institute's Surveillance, Epidemiology, End Results database. Patients categorized into 5 age groups (ages birth to 14, 15-39, 40-59, 60-69, ≥70 years) calendar periods (1980-1989, 1990-1999, 2000-2009, 2010-2017). The outcomes had...
TP53 mutation (TP53mut ) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53mut resistance to venetoclax. The authors investigated the outcomes of patients AML who were treated 10-day decitabine and venetoclax (DEC10-VEN) (ClinicalTrials.gov identifier NCT03404193).Patients newly diagnosed received 20 mg/m2 10 days every 4 6 weeks induction, followed by 5 after...
Abstract Preclinically, enasidenib and azacitidine (ENA + AZA) synergistically enhance cell differentiation, venetoclax (VEN), a small molecule Bcl2 inhibitor (i) is particularly effective in IDH 2 mutated acute myeloid leukemia ( IDH2 mut AML). This open label phase II trial enrolled patients (pts) with documented AML. All received AZA 75 mg/m /d x 7 d/cycle ENA 100 mg QD continuously. Concomitant Bcl2i FLT3i were allowed (NCT03683433).Twenty-six pts (median 68 years, range, 24–88); newly...
Measurable residual disease (MRD) is highly prognostic for relapse and overall survival (OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent "MRD negativity" by standard assays still relapse. We evaluated the clinical impact of a sensitive next-generation sequencing (NGS) MRD assay 74 adults ALL undergoing frontline therapy. Among remission samples that were negative multiparameter flow cytometry (MFC), 46% MRD+ NGS assay. After 1 cycle induction chemotherapy,...
The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates survival compared 5-AZA alone. We hypothesized that the addition to cladribine (CLAD)/low-dose araC (low-dose cytarabine [LDAC]) alternating backbone may further improve outcomes newly diagnosed AML.This is a phase II study investigating CLAD/LDAC in (≥ 60 years) AML. primary objective was composite complete response (CR) rate (CR plus CR incomplete...
The safety and efficacy of combining the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib (IVO) with BCL2 venetoclax (VEN; IVO + VEN) ± azacitidine (AZA; VEN AZA) were evaluated in four cohorts patients IDH1-mutated myeloid malignancies (n = 31). Most (91%) adverse events grade 1 or 2. maximal tolerated dose was not reached. Composite complete remission AZA versus 90% 83%. Among measurable residual disease (MRD)-evaluable (N 16), 63% attained MRD--negative remissions; IDH1 mutation...
PURPOSE Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit intensive chemotherapy. However, FLT3 mutations common mechanism resistance to this regimen. The addition gilteritinib, an oral inhibitor, azacitidine and may improve outcomes in FLT3-mutated AML. METHODS This phase I/II study evaluated azacitidine, venetoclax, gilteritinib two cohorts: (1) were chemotherapy or (2) relapsed/refractory (ClinicalTrials.gov identifier: NCT04140487 )....
Abstract The combination of ponatinib, a third‐generation BCR::ABL1 tyrosine kinase inhibitor, with hyper‐CVAD chemotherapy resulted in high rates complete molecular remissions and survival, without the need for stem cell transplantation (SCT) most patients Philadelphia chromosome(Ph)‐positive acute lymphocytic leukemia (ALL). Confirming these results large cohort longer follow‐up would establish this regimen as new standard care. Adults newly diagnosed Ph‐positive ALL were treated regimen....
Results following hematopoietic stem cell transplantation (HSCT) for TP53-mutated myeloid malignancies are disappointing. Several HSCT centers decline to perform patients with TP53 mutation because of poor outcomes. In this study, we analyzed 240 myelodysplastic syndrome (MDS) or acute leukemia (AML) that underwent HSCT. We aimed identify the benefit most from The primary outcome was progression-free survival (PFS). Fifty-two percent cohort had AML and median age 62. MDS outcomes were...